The purpose of this study was to examine the relationship between scaled speech intelligibility and selected acoustic variables in persons with dysarthria. Control speakers and speakers with amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) produced sentences which were analyzed acoustically and perceptually. The acoustic variables included total utterance durations, segment durations, estimates of the acoustic vowel space, and slopes of formant transitions; the perceptual variables included scaled speech intelligibility and severity of speech involvement. Results indicated that the temporal variables typically differentiated the ALS group, but not the PD group, from the controls, and that vowel spaces were smaller for both neurogenic groups as compared to controls, but only significantly so for the ALS speakers. The relation of these acoustic measures to scaled speech intelligibility is shown to be complex, and the composite results are discussed in terms of sentence vs. single-word intelligibility estimates and their underlying acoustic bases.

Keywords:
Acoustic variables, Dysarthria, Intelligibility
This content is only available via PDF.
© 2001 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.